Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes

Alistair J K Williams, Vito Lampasona, Michael Schlosser, Patricia W Mueller, David L Pittman, William E Winter, Beena Akolkar, Rebecca Wyatt, Cristina Brigatti, Stephanie Krause, Peter Achenbach, Participating Laboratories: Belgian Diabetes Registry

Onderzoeksoutput: Article

30 Citaten (Scopus)

Samenvatting

GAD autoantibodies (GADAs) are sensitive markers of islet autoimmunity and type 1 diabetes. They form the basis of robust prediction models and are widely used for the recruitment of subjects at high risk of type 1 diabetes to prevention trials. However, GADAs are also found in many individuals at low risk of diabetes progression. To identify the sources of diabetes-irrelevant GADA reactivity, we analyzed data from the 2009 and 2010 Diabetes Autoantibody Standardization Program GADA workshop and found that binding of healthy control sera varied according to assay type. The characterization of control sera found positive by radiobinding assay (RBA), but negative by ELISA, showed that many of these sera reacted to epitopes in the N-terminal region of the molecule. This finding prompted development of an N-terminally truncated GAD65 radiolabel, (35)S-GAD65(96-585), which improved the performance of most GADA RBAs participating in an Islet Autoantibody Standardization Program GADA substudy. These detailed workshop comparisons have identified a source of disease-irrelevant signals in GADA RBAs and suggest that N-terminally truncated GAD labels will enable more specific measurement of GADAs in type 1 diabetes.

Originele taal-2English
Pagina's (van-tot)3239-3246
Aantal pagina's8
TijdschriftDiabetes
Volume64
Nummer van het tijdschrift9
DOI's
StatusPublished - sep 2015

Vingerafdruk

Duik in de onderzoeksthema's van 'Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes'. Samen vormen ze een unieke vingerafdruk.

Citeer dit